Efficacy and safety of abatacept compared with etanercept in patients with rheumatoid arthritis in the real world using propensity score matching method

• Published in: Clinical Rheumatology and Related Research Vol. 36; no. 2; pp. 114 - 130
• Main Authors: Takai, Chinatsu, Kodama, Satoru, Murasawa, Akira, Makino, Yuichi, Otani, Hiroshi, Sato, Hiroe, Sakai, Shunsuke, Nakazono, Kiyoshi, Abe, Asami, Ito, Satoshi, Hasegawa, Eriko, Ishikawa, Hajime, Kobayashi, Daisuke, Kurosawa, Yoichi
• Format: Journal Article
• Language: Japanese
• Published: The Japanese Society for Clinical Rheumatology and Related Research 2024; 一般社団法人 日本臨床リウマチ学会
• Subjects: abatacept; efficacy; elderly; rheumatoid arthritis; safety
• ISSN: 0914-8760; 2189-0595
• DOI: 10.14961/cra.36.114

Objective: There are increasing opportunities to use biological disease-modifying antirheumatic drugs and Janus kinase inhibitors, even in elderly patients with rheumatoid arthritis（RA）. We evaluated the use of abatacept（ABT）, which is often used in elderly patients with RA. A comparative study was conducted with etanercept（ETN）, also for RA.Methods: The clinical course data for 143 of 241 patients with RA treated with ABT at Niigata Rheumatic Center and Asahikawa Medical University from July 2010 to March 2018 and those aged 65 years or older were analyzed at 24 months. In addition, the clinical course data of 170 out of 463 patients with RA treated with ETN at the same hospital between May 2008 and March 2018 who were 65 years or older were analyzed and compared using the propensity score matching（PSM）method.Results: The average age of 143 patients treated with ABT was 75.4 ± 6.2 years and disease activity scores improved significantly; the continuation rate at 24 months was 80.4%. The ABT group had significantly lower disease activity, more PSL reduction, and higher continuation rate compared with the ETN group using the PSM method.Conclusion: ABT is an effective treatment for elderly patients with RA over 65 years old and is significantly better at improving disease activity than ETN.